PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
Sets
Sets
Favorites
Favorites
Log in
Log in
AboutPricing
Drug ReportsLiraglutide
Victoza(liraglutide)
Liraglutide, Saxenda, Victoza, Xultophy (liraglutide) is a protein pharmaceutical. Liraglutide was first approved as Victoza on 2009-06-30. It has been approved in Europe to treat obesity, overweight, and type 2 diabetes mellitus. The pharmaceutical is active against glucagon-like peptide 1 receptor.
Download report
Favorite
Top 200 Pharmaceuticals by Retail Sales
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Plot placeholder
Mock data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
nutritional and metabolic diseasesD009750
endocrine system diseasesD004700
signs and symptoms pathological conditionsD013568
diagnosisD003933
physiological phenomenaD010829
Trade Name
FDA
EMA
Liraglutide, Saxenda, Victoza
Combinations
Xultophy
Drug Products
FDA
EMA
Reference product - 351(a)
Reference product - 351(a)
Interchangeable product - 351(k)
Interchangeable product - 351(k)
Biosimilar product - 351(k)
Biosimilar product - 351(k)
Insulin degludec
+
Liraglutide
Tradename
Proper name
Company
Number
Date
Products
Xultophy 100/3.6insulin degludec and liraglutideNovo NordiskN-208583 RX2016-11-21
1 products
Labels
FDA
EMA
Brand Name
Status
Last Update
liraglutideANDA2025-09-11
saxendaNew Drug Application2025-05-01
victozaNew Drug Application2025-05-01
xultophy 100/3.6Biologic Licensing Application2025-05-01
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
type 2 diabetes mellitusEFO_0001360D003924E11
type 1 diabetes mellitusEFO_0001359D003922E10
hyperglycemia—D006943R73.9
Agency Specific
FDA
EMA
Expiration
Code
LIRAGLUTIDE RECOMBINANT, SAXENDA, NOVO
2023-12-04NPP
Patent Expiration
Patent
Expires
Flag
FDA Information
Liraglutide, Saxenda, Novo
99686592037-01-09U-2313, U-2438
81148332025-08-13DS, DP
ATC Codes
A: Alimentary tract and metabolism drugs
— A10: Drugs used in diabetes
— A10A: Insulins and analogues
— A10AE: Insulins and analogues for injection, long-acting
— A10AE56: Insulin degludec and liraglutide
— A10B: Blood glucose lowering drugs, excl. insulins
— A10BJ: Glucagon-like peptide-1 (glp-1) analogues
— A10BJ02: Liraglutide
HCPCS
No data
Clinical
Clinical Trials
502 clinical trials
View more details
Plot placeholder
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Diabetes mellitusD003920EFO_0000400E08-E133716521722143
Type 2 diabetes mellitusD003924EFO_0001360E112113501921123
ObesityD009765EFO_0001073E66.975128739
Type 1 diabetes mellitusD003922EFO_0001359E101341110
Weight lossD015431———21137
Cardiovascular diseasesD002318EFO_0000319I98——23—5
Fatty liverD005234EFO_0003934——1—3—4
Metabolic syndromeD024821EFO_0000195E88.810——12—3
Diastolic heart failureD054144EFO_1000899I50.30———3—3
Insulin resistanceD007333EFO_0002614E88.819——12—3
Show 21 more
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Nutrition disordersD009748EFO_0001069—728—118
OverweightD050177—E66.3314—311
Body weightD001835EFO_0004338——23——5
Prediabetic stateD011236EFO_1001121R73.03—12——3
Glucose intoleranceD018149HP_0000833R73.03—11——2
BulimiaD002032—F50.2——1——1
Feeding and eating disordersD001068—F50——1——1
Binge-eating disorderD056912—F50.2——1——1
Polycystic ovary syndromeD011085EFO_0000660E28.2——1——1
Obstructive sleep apneaD020181EFO_0003918G47.33——1——1
Show 2 more
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Tobacco use disorderD014029—F17—1———1
Smoking cessationD016540EFO_0004319——1———1
Psoriatic arthritisD015535EFO_0003778L40.5—1———1
PsoriasisD011565EFO_0000676L40—1———1
ArthritisD001168EFO_0005856M05-M14—1———1
Non-alcoholic fatty liver diseaseD065626EFO_0003095K75.81—1———1
PouchitisD019449EFO_0003921K91.850—1———1
Parkinson diseaseD010300EFO_0002508G20—1———1
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Healthy volunteers/patients———21————21
HypoglycemiaD007003—E16.21————1
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
CarcinomaD002277—C80.0————11
Thyroid neoplasmsD013964EFO_0003841—————11
Neuroendocrine carcinomaD018278——————11
Papillary thyroid cancerD000077273——————11
Thyroid diseasesD013959—E00-E07————11
Diabetic neuropathiesD003929EFO_1000783—————11
Heart failureD006333EFO_0003144I50————11
HyperglycemiaD006943—R73.9————11
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameLiraglutide
INNliraglutide
Description
Liraglutide is a lipopeptide that is an analogue of human GLP-1 in which the lysine residue at position 27 is replaced by arginine and a hexadecanoyl group attached to the remaining lysine via a glutamic acid spacer. Used as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. It has a role as a glucagon-like peptide-1 receptor agonist and a neuroprotective agent. It is a lipopeptide and a polypeptide.
Classification
Protein
Drug class—
Image (chem structure or protein)Loading
Structure (InChI/SMILES or Protein Sequence)
CCCCCCCCCCCCCCCC(=O)N[C@@H](CCC(O)NCCCC[C@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](C)NC(=O)[C@@H](N)Cc1c[nH]cn1)[C@@H](C)O)[C@@H](C)O)C(C)C)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@H](C(=O)N[C@@H](C)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(=O)O)C(C)C)[C@@H](C)CC)C(=O)O
Identifiers
PDB—
CAS-ID204656-20-2
RxCUI—
ChEMBL IDCHEMBL4524066
ChEBI ID—
PubChem CID16134956
DrugBankDB06655
UNII ID839I73S42A (ChemIDplus, GSRS)
Target
Agency Approved
GLP1R
GLP1R
Organism
Homo sapiens
Gene name
GLP1R
Gene synonyms
NCBI Gene ID
2740
Protein name
glucagon-like peptide 1 receptor
Protein synonyms
GLP-1 receptor, GLP1 receptor, seven transmembrane helix receptor
Uniprot ID
Q99669
Mouse ortholog
Glp1r (14652)
glucagon-like peptide 1 receptor (Q1JQR8)
Alternate
No data
Variants
No data
Financial
Revenue by drug
$
€
£
â‚£
Saxenda – Novo Nordisk
Plot placeholder
Mock data
Subscribe for the real data
Plot placeholder
Mock data
Subscribe for the real data
Xultophy – Novo Nordisk
Plot placeholder
Mock data
Subscribe for the real data
Plot placeholder
Mock data
Subscribe for the real data
Victoza – Novo Nordisk
Plot placeholder
Mock data
Subscribe for the real data
Plot placeholder
Mock data
Subscribe for the real data
Tabular view
Estimated US medical usage
Liraglutide
Total medical expenditures per year (USD, in millions)
Plot placeholder
Mock data
Subscribe for the real data
Number of persons purchased
Plot placeholder
Mock data
Subscribe for the real data
Number of purchases
Plot placeholder
Mock data
Subscribe for the real data
Refill frequency
Plot placeholder
Mock data
Subscribe for the real data
Price per prescription (USD)
Plot placeholder
Mock data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Plot placeholder
Mock data
Subscribe for the real data
Additional graphs summarizing 20,924 documents
View more details
Safety
Black-box Warning
Black-box warning for: Liraglutide, Saxenda, Victoza, Xultophy 100/3.6
Adverse Events
Top Adverse Reactions
Plot placeholder
Mock data
Subscribe for the real data
40,858 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use